Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Insulin Glargine in T2DM and CHF
NCT00766857Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2009
- Primary completion
- Dec 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in heart failure (HF), sponsored by Amsterdam University Medical Center. Primary endpoint: Left Ventricular Ejection Fraction at 11 weeks. Started May 2009; status: completed.
02
Drugs
exenatide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00766857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766857.